| Filed On | Filing |
|---|---|
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES |
| 18 Sep 2026 |
Form 4: Dillione Janet, Director
Received 48,909 shares by exercise or conversion |
| 01 Sep 2026 |
Form 4: Blum Susan, Chief Financial Officer
Gave up 8,424 shares to cover exercise price or tax ($69.9K) |
| 01 Sep 2026 |
Form 4: Hurlburt Elizabeth, Chief Operating Officer
Gave up 8,076 shares to cover exercise price or tax ($67K) |
| 01 Sep 2026 |
Form 4: Zelnick Kaufman Beth, Chief Legal Officer
Gave up 8,424 shares to cover exercise price or tax ($69.9K) |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | 8-K: Other Events |
| 02 Jul 2026 | 8-K: Other Events |
| 01 Jul 2026 | 8-K: Changes in Registrant's Certifying Accountant |
| 25 Jun 2026 | S-8 POS |
| 24 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 12 Jun 2026 | SCHEDULE 13G/A |
| 12 Jun 2026 | SCHEDULE 13G/A |
| 08 Jun 2026 | 8-K: Regulation FD Disclosure |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | 10-Q |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 29 Apr 2026 | ARS |
| 29 Apr 2026 | DEFINITIVE ADDITIONAL MATERIALS |
Loading...
